Abstract 3315: Evaluating biomarker potential of germline genomic factors for predicting clinical outcomes in prostate cancer

Abstract

Abstract Prostate cancer is the second-most diagnosed cancer and the second leading cause of cancer death in American men. Early detection is common, but is followed by the more challenging task of prognosing a highly variable clinical course. Current clinical risk-assessment strategies such as serum abundance of prostate specific antigen (PSA), tumor size & extent, and tumor grade based on biopsy are highly imprecise: over a third of patients are over-treated. An improved method of risk stratification may lie in hereditary factors. Prostate cancer is one of the most strongly inherited (h2 = 57%), with accumulating evidence associating rare variants, common variants, and genetic ancestry to clinical outcomes. We have performed germline sequencing on blood from thousands of patients diagnosed with localized prostate cancer and with extensive follow-up data. We quantify the interactions of rare and common variants, and demonstrate that germline features provide insights into patient outcomes and optimal management strategies. Citation Format: Nicole Zeltser, Kathleen E. Houlahan, Sarah M. Al-Hiyari, Stefan E. Eng, Yash Patel, Takafumi N. Yamaguchi, Shu Tao, Rong Rong Huang, Robert E. Reiter, Huihui Ye, Adam S. Kinnaird, Paul C. Boutros. Evaluating biomarker potential of germline genomic factors for predicting clinical outcomes in prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3315.